Zai LabZLAB +0.79%64 3-1 Month Momentum % is -15.98% as of Jul. 02, 2026. GuruFocus rates ZLAB with a GF Score™ of 64/100 and a GF Value™ of $30.27 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 1,386 Biotechnology companies, Zai Lab ranks worse than 72.08% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-02), Zai Lab's 3-1 Month Momentum % is -15.98%.
The industry rank for Zai Lab's 3-1 Month Momentum % or its related term are showing as below:
ZLAB's 3-1 Month Momentum % is ranked worse than 72.08% of 1386
companies
in the Biotechnology industry
Industry Median: -5.29
vs ZLAB: -15.98
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Zai Lab 3-1 Month Momentum % Related Terms
ZLAB vs STOK, ADMA, VRDN: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Zai Lab's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zai Lab 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zai Lab's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Zai Lab's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zai Lab (ZLAB) has a 3-1 Month Momentum % of -15.98% as of Jul. 02, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Zai Lab and its competitors. According to the industry distribution chart, Zai Lab ranks #999 out of 1386 companies in the Biotechnology industry, placing it in the top 72.1%.
Is Zai Lab's 3-1 Month Momentum % too high?
Zai Lab's current 3-1 Month Momentum % is -15.98%. Based on the distribution chart, Zai Lab ranks #999 out of 1386 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Zai Lab has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zai Lab's 3-1 Month Momentum % compare to STOK and ADMA?
According to the Biotechnology industry distribution chart, Zai Lab ranks #999 out of 1386 companies for 3-1 Month Momentum %. This places Zai Lab in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Zai Lab and its competitors. Zai Lab's current 3-1 Month Momentum % is -15.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zai Lab stock overvalued right now?
Based on GuruFocus' analysis, Zai Lab (ZLAB) is currently considered Possible Value Trap. The stock's GF Value™ is $30.27, compared to a current price of $19.16 — trading 36.7% below its estimated fair value. The current 3-1 Month Momentum % is -15.98%. Zai Lab's overall GF Score™ is 64/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Zai Lab (ZLAB), the current 3-1 Month Momentum % is -15.98% as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zai Lab (ZLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued.
The current stock price of $19.16 is trading 36.7% below its estimated GF Value™ of $30.27.
GuruFocus considers Zai Lab to be Possible Value Trap.
Key valuation signals for ZLAB:
3-1 Month Momentum %: -15.98%
GF Value™: $30.27 vs. price of $19.16 (36.7% below fair value)
No single metric tells the full story. See the ZLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
64GF Score
Get the complete analysis for ZLAB
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLAB has been successfully added to your 